A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

NCT04861779 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory B-Cell Malignancies

Interventions

DRUG: HSK29116

Sponsor

Haisco Pharmaceutical Group Co., Ltd.